GANX gain Therapeutics CEO Gene mack issues letter to shareholders and provides operational update Gain Therapeutics - to commence phase 2 s

GANX gain Therapeutics CEO Gene mack issues letter to shareholders and provides operational update Gain Therapeutics - to commence phase 2 study of rexaceract in Q3 2026